Cargando…
The Chimeric Antigen Receptor Detection Toolkit
Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from preclinical models to clinical adoption. For instance,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431616/ https://www.ncbi.nlm.nih.gov/pubmed/32849635 http://dx.doi.org/10.3389/fimmu.2020.01770 |
_version_ | 1783571620419338240 |
---|---|
author | Hu, Yifei Huang, Jun |
author_facet | Hu, Yifei Huang, Jun |
author_sort | Hu, Yifei |
collection | PubMed |
description | Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from preclinical models to clinical adoption. For instance, CAR-staining/labeling agents have enabled flow cytometry analysis, imaging applications, cell sorting, and high-dimensional clinical profiling. Molecular assays, such as quantitative polymerase chain reaction, integration site analysis, and RNA-sequencing, have characterized CAR transduction, expression, and in vivo CAR-T cell expansion kinetics. In vitro visualization methods, including confocal and total internal reflection fluorescence microscopy, have captured the molecular details underlying CAR immunological synapse formation, signaling, and cytotoxicity. In vivo tracking methods, including two-photon microscopy, bioluminescence imaging, and positron emission tomography scanning, have monitored CAR-T cell biodistribution across blood, tissue, and tumor. Here, we review the plethora of CAR detection methods, which can operate at the genomic, transcriptomic, proteomic, and organismal levels. For each method, we discuss: (1) what it measures; (2) how it works; (3) its scientific and clinical importance; (4) relevant examples of its use; (5) specific protocols for CAR detection; and (6) its strengths and weaknesses. Finally, we consider current scientific and clinical needs in order to provide future perspectives for improved CAR detection. |
format | Online Article Text |
id | pubmed-7431616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74316162020-08-25 The Chimeric Antigen Receptor Detection Toolkit Hu, Yifei Huang, Jun Front Immunol Immunology Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from preclinical models to clinical adoption. For instance, CAR-staining/labeling agents have enabled flow cytometry analysis, imaging applications, cell sorting, and high-dimensional clinical profiling. Molecular assays, such as quantitative polymerase chain reaction, integration site analysis, and RNA-sequencing, have characterized CAR transduction, expression, and in vivo CAR-T cell expansion kinetics. In vitro visualization methods, including confocal and total internal reflection fluorescence microscopy, have captured the molecular details underlying CAR immunological synapse formation, signaling, and cytotoxicity. In vivo tracking methods, including two-photon microscopy, bioluminescence imaging, and positron emission tomography scanning, have monitored CAR-T cell biodistribution across blood, tissue, and tumor. Here, we review the plethora of CAR detection methods, which can operate at the genomic, transcriptomic, proteomic, and organismal levels. For each method, we discuss: (1) what it measures; (2) how it works; (3) its scientific and clinical importance; (4) relevant examples of its use; (5) specific protocols for CAR detection; and (6) its strengths and weaknesses. Finally, we consider current scientific and clinical needs in order to provide future perspectives for improved CAR detection. Frontiers Media S.A. 2020-08-11 /pmc/articles/PMC7431616/ /pubmed/32849635 http://dx.doi.org/10.3389/fimmu.2020.01770 Text en Copyright © 2020 Hu and Huang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Hu, Yifei Huang, Jun The Chimeric Antigen Receptor Detection Toolkit |
title | The Chimeric Antigen Receptor Detection Toolkit |
title_full | The Chimeric Antigen Receptor Detection Toolkit |
title_fullStr | The Chimeric Antigen Receptor Detection Toolkit |
title_full_unstemmed | The Chimeric Antigen Receptor Detection Toolkit |
title_short | The Chimeric Antigen Receptor Detection Toolkit |
title_sort | chimeric antigen receptor detection toolkit |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431616/ https://www.ncbi.nlm.nih.gov/pubmed/32849635 http://dx.doi.org/10.3389/fimmu.2020.01770 |
work_keys_str_mv | AT huyifei thechimericantigenreceptordetectiontoolkit AT huangjun thechimericantigenreceptordetectiontoolkit AT huyifei chimericantigenreceptordetectiontoolkit AT huangjun chimericantigenreceptordetectiontoolkit |